Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
Lumos Pharma, Inc. (LUMO)
Company Research
Source: GlobeNewswire
AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials has been accepted for presentation at the XXXI Meeting of the Latin American Society of Paediatric Endocrinology (Sociedad Latinoamericana de Endocrinología Pediátrica), or SLEP 2024, to be held September 11-14, 2024 in Santiago, Chile. Abstract Presentation: Friday, September 13th – E-poster Session 2 – 1:15-2:30PM Local Time Abstract entitled, LUM-201 Restores Growth Hormone Secretion and Promotes Growth in Moderate Pediatric Growth Hormone Deficiency (PGHD): Phase 2 Topline Results from OraGrowtH210 and OraGrowtH212 Trials (Rossana Román, MD, et al) About Lumos Pharma Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for
Show less
Read more
Impact Snapshot
Event Time:
LUMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUMO alerts
High impacting Lumos Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
LUMO
News
- Lumos Pharma, Inc. (NASDAQ: LUMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.MarketBeat
- Lumos Pharma, Inc. (NASDAQ: LUMO) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.MarketBeat
- Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024GlobeNewswire
- Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Lumos Pharma, Inc. (NASDAQ: LUMO) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $16.00 to $13.00. They now have an "outperform" rating on the stock.MarketBeat
LUMO
Earnings
- 8/1/24 - Beat
LUMO
Sec Filings
- 8/6/24 - Form 4
- 8/5/24 - Form 4
- 8/5/24 - Form 4
- LUMO's page on the SEC website